Pulsed electric field medical devices for surgical soft-tissue ablation.
Perceptive Advisors
Activity from announced rounds
Perceptive Advisors is the healthcare investment manager named in Superluminal’s financing and retained company records.
Recorded funding activity
Superluminal develops small-molecule medicines using structural and experimental methods. Vaderis develops an oral treatment for hereditary hemorrhagic telangiectasia, while Imperative develops thromboembolic interventions. The manager remains separate from the Xontogeny venture arm.
- Rounds participated in
- 7
- Confirmed lead rounds
- 1 3 roles undisclosed
- New companies
- 7 First participation on record · 0 follow-on
- Funding in participating rounds
- $952M 6 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
7 in all activityDistalmotion develops the DEXTER robotic surgery system for hospitals and outpatient surgery centres.
Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.
Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia
Develops treatments for patients suffering from thromboembolic disease
Provides in-network psychiatric care using AI-powered technology
Kardigan develops cardiovascular medicines that target specific biological drivers of heart disease and the patient groups most likely to respond.